Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

The EU drugs regulator says Gilead Sciences’ antiviral drug remdesivir should be made available for people seriously ill with COVID-19, despite limited data on its efficacy. The EMA’s human ...

CompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...

Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...

Gilead Sciences reported strong fourth-quarter ... Veklury sales experienced a steep 53% decline to $337 million, mirroring decreased COVID-19 hospitalizations, which was expected as the pandemic ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other stocks that analysts think will go up. The S&P 500 index touched an all-time high ...

Gilead Sciences Inc. GILD stock surged to a new ... including Veklury sales of $1.4 billion, which is its COVID-19 treatment. 2) Gilead’s HIV, Oncology, and Liver Disease Franchise Continues ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.